2024-08-25 - Analysis Report
## PFE Stock Analysis Report

**Company Overview:**  Pfizer Inc. (PFE) is a multinational pharmaceutical corporation that develops, manufactures, and distributes medicines and vaccines.

**1. Performance vs. S&P 500 (VOO):**

PFE has significantly underperformed the S&P 500 over the period analyzed. 
* PFE's cumulative return is -28.46%, while the S&P 500 (VOO) has returned 71.75%.
* The relative divergence shows PFE currently lagging behind the S&P 500 by 100.19%, which is at the bottom of its historical range (1.35% on the relative divergence scale).

**2. Recent Price Movement:**

* PFE is currently trading at $28.90.
* The stock is slightly above its 5-day moving average ($28.88) but below its 20-day ($29.33) and 60-day ($28.82) moving averages. This suggests a short-term consolidation phase with a possible bearish bias.

**3. Technical Indicators:**

* **RSI (47.69):** The RSI is close to the neutral level of 50, indicating neither overbought nor oversold conditions.
* **PPO (-0.21):** The PPO is slightly negative, suggesting a slight bearish momentum in the short term.
* **Delta_Previous_Relative_Divergence (-8.35):** The negative value indicates a recent downward trend in relative divergence, further supporting the bearish momentum.

**4. Recent Earnings and Outlook:**

PFE's latest earnings report (2024-07-30) showed EPS of $0.60, exceeding the estimated $0.458. This positive surprise could potentially indicate a positive outlook for the company. 
However, it's important to consider the following:

| Date        | EPS  | Expected EPS |
|--------------|------|-------------|
| 2024-07-30  | 0.60 | 0.458        |
| 2024-05-01  | 0.82 | 0.516        |
| 2024-01-30  | 0.10 | -0.19        |
| 2023-10-31  | -0.17| -0.32        |
| 2023-08-01  | 0.67 | 0.56         |

While the latest earnings beat expectations, there have been periods of underperformance in the past few quarters. This inconsistency suggests a need for further observation to understand the long-term sustainability of this positive trend.

**5. Overall Analysis:**

PFE is currently underperforming the S&P 500. Technical indicators point towards a potential short-term bearish momentum. While the latest earnings report was positive, it's crucial to analyze the long-term trend considering the historical performance inconsistencies. Investors should carefully consider this information before making any investment decisions.

**6. Recommendations:**

* **Short-Term:** Investors seeking a short-term investment opportunity might consider a wait-and-see approach, observing the market reaction to the recent earnings report and the upcoming earnings releases.
* **Long-Term:** Long-term investors should conduct further research to assess PFE's long-term growth potential, considering its historical performance, current market conditions, and the evolving pharmaceutical landscape.

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. Investors are advised to consult with a qualified financial advisor before making any investment decisions.